Objective: This study sought to compare pre-intervention patient characteristics and post-intervention outcomes in a naturalistic sample of adolescent inpatients with treatment-resistant psychotic symptoms who received either electroconvulsive therapy (ECT) or clozapine.
Methods: Data of adolescents with schizophrenia/schizoaffective disorder receiving ECT or clozapine were retrospectively collected from two tertiary-care psychiatry-teaching university hospitals. Subscale scores of the Positive and Negative Symptom Scale (PANSS) factors were calculated according to the five-factor solution. Baseline demographics, illness characteristics, and post-intervention outcomes were compared.
Results: There was no significant difference between patients receiving ECT ( = 13) and clozapine ( = 66) in terms of age, sex, and the duration of hospital stay. The ECT group more commonly had higher overall illness and aggression severity. Smoking was less frequent in the clozapine group. Baseline resistance/excitement symptom severity was significantly higher in the ECT group, while positive, negative, affect, disorganisation, and total symptom scores were not. Both interventions provided a significant reduction in PANSS scores with large effect sizes.
Conclusion: Both ECT and clozapine yielded high effectiveness rates in adolescents with treatment-resistant schizophrenia/schizoaffective disorder. Youth receiving ECT were generally more activated than those who received clozapine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13651501.2022.2160764 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
Am J Psychiatry
January 2025
Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore (Aaronson, Miller, LaPratt, Swartz, Shoultz, Lauterbach); Department of Psychiatry, University of Maryland, Baltimore (Aaronson, van der Vaart, Lauterbach); VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Palo Alto, CA (Suppes); Departments of Psychiatry and Radiology, Columbia University, New York (Sackeim).
Article Synopsis
- The study focused on evaluating the safety and effectiveness of psilocybin for patients with severe treatment-resistant depression (TRD), who had not benefited from at least five previous treatments.
- Conducted over 12 weeks at Sheppard Pratt Hospital, patients received a single 25 mg dose of synthetic psilocybin and underwent therapy sessions before and after dosing, assessing their depression levels mainly with the Montgomery-Åsberg Depression Rating Scale (MADRS).
- Results showed significant reductions in depressive symptoms at both 3 weeks and 12 weeks post-treatment, indicating psilocybin’s potential as a viable option for individuals with severe TRD, although those with comorbid PTSD experienced less improvement.
Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.
Neuropsychopharmacology
December 2024
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TRD) in order to facilitate evidence-based choices. A literature search of PubMed, Cochrane Library, and Embase from inception until April 13th, 2023 identified randomized, controlled trials (RCTs) of adults with depression who had not responded to at least two antidepressant trials; all RCTs had ≥10 participants per study arm, and participants with bipolar or psychotic depression were excluded. The Cochrane Risk of Bias Tool-2 was used to assess study quality.
View Article and Find Full Text PDFPilot Study of Cerebral Hemodynamics in Depressive Patient Under Electroconvulsive Therapy.
Neuropsychiatr Dis Treat
December 2024
Research Center of Educational Neuroscience, School of Educational Science, Huazhong University of Science and Technology, Wuhan City, Hubei Province, People's Republic of China.
Article Synopsis
- Major depressive disorder (MDD) is a complex condition that can be hard to treat, and Electroconvulsive therapy (ECT) shows promise but its workings are not fully understood.
- This study used functional Near-Infrared Spectroscopy (fNIRS) to compare the brain activity of a male MDD patient to that of 26 healthy controls before and after ECT, focusing on how ECT affects cerebral blood flow and brain networks.
- Results indicated that the MDD patient had lower brain activity and connectivity at the start, but after ECT, these measures improved significantly, suggesting that ECT can effectively alter brain function in depressed patients and that fNIRS is a valuable tool for studying these changes.
Acceptability, Feasibility, and Effectiveness of Concurrent High-Definition Transcranial Direct Current Stimulation and Cue Exposure in Cannabis Use Disorder: A Pilot Double-Blind Randomized Controlled Trial.
J ECT
December 2024
From the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objectives: We studied the acceptability, feasibility, tolerability, and preliminary effectiveness of combined cue exposure and anodal high-definition transcranial direct current stimulation (HD-tDCS) on the right dorsolateral prefrontal cortex (DLPFC) on cannabis craving in cannabis use disorder (CUD).
Methods: We randomly assigned 48 participants equally in 4 groups: A, tDCS and cannabis cue exposure; B, tDCS and neutral image; C, sham tDCS and cue exposure; and D, sham tDCS and neutral image. The images were validated by Delphi consensus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!